TuHURA Biosciences, Inc.
HURAHealthcare|Biotechnology|US
$1.63
+0.02 (+1.24%)
Tangible Book / Share
$0.12
Cash / Share
$0.02
Financials
Financial Snapshot
Market Cap
$103.9M
Enterprise Value
$103.3M
Revenue (TTM)
$0.00
Net Income (TTM)
-$30.6M
Cash & Investments
$996.0K
Net Cash
$589.0K
Free Cash Flow (TTM)
-$29.9M
Operating CF (TTM)
-$29.7M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$996.0K
Quarterly Burn
$7.4M
Monthly Burn
$2.5M
Est. Runway
~0.1 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $6.6M | $6.0M | $3.7M | $2.4M | $10.5M | $5.5M | $14.3M | $3.7M | $12.7M | $3.6M | $996.0K | |
| Operating Cash Flow | -$8.0M | -$9.9M | -$6.3M | -$7.9M | -$18.9M | -$6.6M | -$7.5M | -$12.0M | -$14.7M | -$27.6M | -$29.7M | |
| Free Cash Flow | -$8.0M | $0.00 | -$6.3M | -$7.9M | -$18.9M | -$6.6M | -$7.5M | -$12.0M | -$14.8M | -$27.7M | -$29.9M | |
| Capital Expenditure | $0.00 | $9.9M | $5.00 | $0.00 | -$8.0K | -$3.3K | -$36.3K | -$79.2K | -$57.9K | -$76.1K | -$213.7K | |
| Financing Cash Flow | $8.5M | $9.2M | $4.1M | $6.6M | $26.0M | $7.0M | $16.3M | $2.7M | $29.8M | $19.9M | $22.4M |
R&D Spending
R&D (TTM)
$22.9M
R&D Intensity
—
R&D Growth vs Prior
+11.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $5.0M | $7.1M | $3.7M | $3.6M | $11.8M | $15.2M | $9.3M | $2.7M | $13.3M | $20.5M | $22.9M | |
| SG&A | $3.3M | $4.0M | $4.7M | $4.5M | $9.7M | $7.4M | $5.4M | $5.7M | $3.9M | $7.6M | $4.6M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $16.7K | $24.5K | $16.3K | $10.0K | $32.0K | $60.0K | $60.0K | $55.0K | $0.00 | $0.00 | $23.5K | |
| Gross Profit | -$16.7K | -$24.5K | -$16.3K | -$10.0K | -$32.0K | -$60.0K | -$60.0K | -$55.0K | $0.00 | $0.00 | -$23.5K | |
| R&D | $5.0M | $7.1M | $3.7M | $3.6M | $11.8M | $15.2M | $9.3M | $2.7M | $13.3M | $20.5M | $22.9M | |
| SG&A | $3.3M | $4.0M | $4.7M | $4.5M | $9.7M | $7.4M | $5.4M | $5.7M | $3.9M | $7.6M | $4.6M | |
| Operating Income | -$8.3M | -$11.2M | -$8.4M | -$8.1M | -$21.6M | -$22.7M | -$14.8M | -$8.5M | -$17.6M | -$31.8M | -$31.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $120.0K | $629.3K | $0.00 | $18.7K | $4.1M | $625.3K | $1.1M | |
| Pretax Income | -$8.1M | -$11.1M | -$8.0M | -$9.1M | -$38.3M | -$22.7M | -$14.6M | -$8.3M | -$21.7M | -$30.1M | -$30.6M | |
| Net Income | -$8.1M | -$11.1M | -$8.0M | -$9.1M | -$38.3M | -$22.7M | -$14.6M | -$8.3M | -$21.7M | -$30.1M | -$30.6M | |
| EPS (Diluted) | -12950.00 | -9491.47 | -5524.99 | -1532.00 | -2805.84 | -903.03 | -324.48 | -11.29 | -1.21 | -0.63 | -0.54 | |
| EBITDA | -$8.1M | -$11.1M | -$8.0M | -$9.1M | -$38.1M | -$21.7M | -$14.3M | -$8.1M | -$17.4M | -$29.4M | -$29.4M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.05 | 0.75 | 18.66 | 47.93 | 63.96 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.6M | $6.0M | $3.7M | $2.4M | $10.5M | $5.5M | $14.3M | $3.7M | $12.7M | $3.6M | $996.0K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $7.9M | $7.0M | $4.0M | $2.8M | $11.8M | $5.7M | $14.7M | $4.2M | $19.6M | $4.6M | $1.7M | |
| Total Assets | $7.9M | $7.1M | $4.0M | $2.9M | $13.5M | $6.4M | $15.2M | $4.4M | $20.0M | $27.4M | $31.7M | |
| Total Current Liabilities | $1.3M | $1.6M | $2.1M | $2.7M | $2.8M | $7.2M | $2.9M | $3.6M | $5.3M | $5.9M | $9.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.3M | $0.00 | $303.6K | $192.8K | |
| Total Liabilities | $1.3M | $1.6M | $2.1M | $2.7M | $3.0M | $7.2M | $2.9M | $5.9M | $5.4M | $6.4M | $13.2M | |
| Stockholders' Equity | $6.6M | $5.4M | $2.0M | $263.0K | $10.6M | -$747.8K | $12.3M | -$1.6M | $14.6M | $20.9M | $18.5M | |
| Retained Earnings | -$41.1M | -$52.4M | -$60.6M | -$69.7M | -$111.2M | -$49.5M | -$59.2M | -$88.5M | -$111.1M | -$141.2M | -$157.9M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.0M | -$9.9M | -$6.3M | -$7.9M | -$18.9M | -$6.6M | -$7.5M | -$12.0M | -$14.7M | -$27.6M | -$29.7M | |
| Capital Expenditure | $0.00 | $9.9M | $5.00 | $0.00 | -$8.0K | -$3.3K | -$36.3K | -$79.2K | -$57.9K | -$76.1K | -$213.7K | |
| Free Cash Flow | -$8.0M | $0.00 | -$6.3M | -$7.9M | -$18.9M | -$6.6M | -$7.5M | -$12.0M | -$14.8M | -$27.7M | -$29.9M | |
| Investing Cash Flow | -$21.0K | -$12.6K | $0.00 | $0.00 | $964.0K | -$3.3K | -$36.3K | -$1.3M | -$6.1M | -$1.3M | -$213.7K | |
| Financing Cash Flow | $8.5M | $9.2M | $4.1M | $6.6M | $26.0M | $7.0M | $16.3M | $2.7M | $29.8M | $19.9M | $22.4M | |
| Issuance of Stock | $8.5M | $9.3M | $4.1M | $6.6M | $26.1M | $5.6M | $0.00 | $0.00 | $5.0M | $21.9M | $20.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$24.8K | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $294.1K | -$350.0K | $2.7M | $28.6M | $617.0K | $4.0M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $654.5K | $218.3K | $478.9K | $2.0M | $6.4M | $5.7M | |
| Net Change in Cash | $428.8K | -$614.0K | -$2.3M | -$1.3M | $8.1M | $477.9K | $8.7M | -$10.6M | $9.0M | -$9.0M | -$7.5M |
Dilution Tracker
Shares outstanding grew 323929.5% over 5 years — significant dilution
Shares Outstanding
64M
5-Year Share Growth
+323929.5%
Stock Issuance (TTM)
$20.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.05 | 0.75 | 18.66 | 47.93 | 63.96 | |
| Change vs Prior % | — | 73.3% | 23.4% | 305.7% | 147.8% | 88.1% | 66.3% | 1526.7% | 2378.7% | 156.8% | 33.5% | |
| Stock Issuance | $8.5M | $9.3M | $4.1M | $6.6M | $26.1M | $5.6M | $0.00 | $0.00 | $5.0M | $21.9M | $20.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$24.8K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $654.5K | $218.3K | $478.9K | $2.0M | $6.4M | $5.7M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -122.9% | -204.9% | -409.1% | -3470.0% | -362.0% | 3030.3% | -119.1% | 533.8% | -148.6% | -143.6% | -154.3% | |
| ROA % | -102.2% | -157.4% | -199.3% | -310.6% | -282.8% | -354.0% | -96.4% | -190.7% | -108.6% | -109.9% | -96.5% | |
| ROIC % | -125.9% | -205.6% | -426.9% | -3096.6% | -200.4% | 21862.0% | -118.9% | -1074.9% | -119.3% | -145.7% | -137.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -62.2% | -47.0% | 33.3% | 38.8% | -220.0% | -87.5% | 0.0% | 8.3% | 100.0% | 0.0% | |
| Operating Income | -33.9% | -34.3% | 24.8% | 3.0% | -164.9% | -5.1% | 34.8% | 42.9% | -108.8% | -80.2% | |
| Net Income | 8.8% | -37.8% | 27.7% | -13.4% | -319.7% | 40.8% | 35.4% | 43.2% | -160.6% | -38.6% | |
| EPS (Diluted) | 10.8% | 26.7% | 41.8% | 72.3% | -83.1% | 67.8% | 64.1% | 96.5% | 89.3% | 47.9% | |
| Operating Cash Flow | -55.8% | -22.8% | 35.8% | -25.3% | -137.9% | 65.2% | -14.4% | -59.2% | -23.2% | -87.6% | |
| Free Cash Flow | -55.8% | 100.0% | 0.0% | -25.3% | -138.0% | 65.2% | -14.9% | -59.5% | -22.9% | -87.4% | |
| R&D Expense | 48.9% | 42.6% | -48.7% | -0.9% | 225.5% | 28.4% | -38.6% | -71.4% | 400.8% | 54.0% | |
| SG&A Expense | 16.1% | 21.7% | 17.5% | -4.6% | 115.9% | -23.4% | -27.2% | 5.7% | -32.4% | 95.8% | |
| Total Assets | 24.5% | -10.6% | -42.9% | -27.2% | 361.0% | -52.7% | 137.4% | -71.3% | 357.8% | 37.0% | |
| Book Value / Share | 23.2% | -52.3% | -70.7% | -96.7% | 1523.3% | -103.8% | 1089.2% | -100.8% | 137.8% | -44.1% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -78.5% | 1596.5% | -91.4% | 245.6% | |
| Diluted Shares | 9.9% | 73.3% | 23.4% | 305.7% | 147.8% | 88.1% | 66.3% | 1526.7% | 2378.7% | 156.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B5.64
10Y Low / Med / High0.03 / 0.16 / 5.23
EV/EBITDAAt Loss
10Y Low / Med / High0.19 / 0.45 / 0.97
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.12
Cash / Share
$0.02
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.09 | -0.04 | -0.01 | -0.02 | -0.04 | -0.03 | -0.02 | -0.49 | -3.38 | -1.20 | -3.02 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.12 | 0.07 | 0.05 | 0.78 | 0.16 | -0.95 | 0.03 | -2.69 | 5.23 | 1.73 | 5.64 | |
| EV/EBITDA | 0.72 | 0.50 | 0.45 | 0.24 | 0.23 | 0.19 | 0.97 | -0.35 | -3.67 | -1.14 | -3.51 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-5.35
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $10.5M | $16.9M | $51.6M |
| Net Income | -$26.4M | -$29.1M | $1.1M |
| EPS | $-0.56 | $-0.61 | $-0.16 |
| # Analysts (EPS) | 3 | 3 | 3 |